Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

ISIS PHARMACEUTICALS, INC. (ISIS)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2018 600 M
EBIT 2018 -37,8 M
Net income 2018 -50,8 M
Finance 2018 12,3 M
Yield 2018 -
Sales 2019 712 M
EBIT 2019 9,92 M
Net income 2019 27,4 M
Finance 2019 253 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 229,25
EV / Sales2018 9,60x
EV / Sales2019 7,75x
Capitalization 5 774 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology.It operates through the Ionis Core and Akcea Therapeutics segments.The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.The... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
05:44pIONIS PHARMACEUTICALS : Gains on Biogen Hookup
AQ
04:10pIONIS PHARMACEUTICALS : to get $1 billion cash in expanded deal with Biogen
AQ
12:31pBIOGEN : and Ionis Expand Strategic Collaboration to Develop Drug Candidates for..
BU
04/19IONIS PHARMACEUTICALS : and AstraZeneca Advance New Drug for NASH
AQ
04/10IONIS PHARMACEUTICALS : earns $30 million upfront in third deal with AstraZeneca
AQ
04/02Why Alnylam Pharmaceuticals, Inc. Is Tanking Today
AQ
04/02Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
AQ
03/28IONIS PHARMACEUTICALS : Provides Corporate Update at 2018 Annual Meeting of Stoc..
AQ
03/23IONIS PHARMACEUTICALS : Provides Corporate Update at 2018 Annual Meeting of Stoc..
PR
03/22IONIS PHARMACEUTICALS : and Akcea Partner to Commercialize Inotersen for hATTR
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
ISIS PHARMACEUTICALS - 2014
A resistance as obstacle
SELL
More Strategies
News from SeekingAlpha
2015Game Plan For The Week - Cramer's Mad Money (12/18/15) 
2015PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr.. 
2015Isis Pharma has had enough, name changed to Ionis Pharmaceuticals 
2015Bear Afoot? No Recession Needed For A Possible Sighting 
2015PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui.. 
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 13
Average target price 61,3 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
Brett P. Monia Chief Operating Officer
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
Sanjay Bhanot Chief Medical Officer
B. Lynne Parshall Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%5 774
CELLTRION, INC.--.--%31 274
IQVIA HOLDINGS INC0.17%20 671
LONZA GROUP-6.84%18 497
NEKTAR THERAPEUTICS56.92%14 892
INCYTE CORPORATION-26.02%14 841